Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 02, 2022 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics to Present at the Cowen 42nd Annual Health Care Conference

NEW YORK, March 02, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS)...
March 01, 2022 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

Company to host conference call today at 8:00 AM Eastern NEW YORK, March 01, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel...
February 15, 2022 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 1, 2022

Axsome to host conference call and webcast on Tuesday, March 1, 2022 at 8:00 AM Eastern Time NEW YORK, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a...
February 11, 2022 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

NEW YORK, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS)...
November 08, 2021 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update

Company to host conference call today at 8:00 AM Eastern NEW YORK, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies...
October 20, 2021 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics to Report Third Quarter 2021 Financial Results on November 8, 2021

Axsome to host conference call and webcast on Monday, November 8, 2021 at 8:00 AM Eastern Time NEW YORK, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a...
October 18, 2021 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Expands Term Loan Facility with Hercules Capital to $300 Million

$100 million now available upon the potential FDA approval of AXS-05 NEW YORK, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing...
September 16, 2021 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Initiates SYMPHONY Phase 3 Trial of AXS-12 in Narcolepsy

NEW YORK, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS)...
September 14, 2021 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-07 for the Acute Treatment of Migraine

NEW YORK, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS)...
August 23, 2021 06:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Provides Update on the New Drug Application for AXS-05 for the Treatment of Major Depressive Disorder

NEW YORK, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS)...